Healthcare [ 12/13 ] | Biotechnology [ 116/164 ]
NASDAQ | Common Stock
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States.
It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 7, 24 | -1.21 Increased by +9.02% | -1.42 Increased by +14.79% |
| Feb 27, 24 | 1.73 Increased by +420.37% | -1.01 Increased by +271.29% |
| Nov 8, 23 | -1.22 Increased by +21.79% | -1.36 Increased by +10.29% |
| Aug 8, 23 | -1.08 Decreased by -5.88% | -1.42 Increased by +23.94% |
| May 10, 23 | -1.33 Decreased by -31.68% | -1.34 Increased by +0.75% |
| Feb 28, 23 | -0.54 Increased by +43.16% | -1.33 Increased by +59.40% |
| Nov 7, 22 | -1.56 Decreased by -271.43% | -1.31 Decreased by -19.08% |
| Aug 9, 22 | -1.02 Increased by +17.07% | -1.08 Increased by +5.56% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 316.19 M Increased by +1.48 K% | 142.80 M Increased by +472.36% | Increased by +45.16% Increased by +123.60% |
| Sep 30, 23 | 17.19 M Increased by +8.82% | -96.09 M Increased by +12.31% | Decreased by -558.88% Increased by +19.42% |
| Jun 30, 23 | 20.12 M Increased by +20.80% | -82.78 M Decreased by -70.67% | Decreased by -411.49% Decreased by -41.28% |
| Mar 31, 23 | 24.21 M Increased by +187.10% | -84.03 M Decreased by -52.25% | Decreased by -347.12% Increased by +46.97% |
| Dec 31, 22 | 20.04 M Decreased by -60.76% | -38.35 M Increased by +40.61% | Decreased by -191.39% Decreased by -51.37% |
| Sep 30, 22 | 15.80 M Increased by +1.97 K% | -109.58 M Decreased by -289.70% | Decreased by -693.56% Increased by +81.18% |
| Jun 30, 22 | 16.65 M Increased by +277.43 K% | -48.50 M Increased by +36.40% | Decreased by -291.26% Increased by +99.98% |
| Mar 31, 22 | 8.43 M Increased by +140.43 K% | -55.19 M Increased by +72.62% | Decreased by -654.55% Increased by +99.98% |